Technology Bundle ID

Novel Targets to Prevent Borrelia burgdorferi Infection and Lyme Disease

Linked ID
Lead Inventors
Robert Gilmore (CDC)
Development Status
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
B. burgdorferi-infected ticks can cause Lyme disease in mammalian hosts. This technology relates to the use of B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease vaccine candidates. In vivo animal studies demonstrate these outer surface proteins inhibit tick-to-host B. burgdorferi transmission. Presently, there is no vaccine approved for Lyme disease.
Commercial Applications
  • B. burgdorferi/Lyme disease vaccine development
  • B. burgdorferi diagnostics
  • Prevention of B. burgdorferi infection by passive immunity
  • Zoonotic/tick-borne disease surveillance
  • Public health vaccination programs against Lyme disease
Competitive Advantages
  • Currently no approved Lyme disease vaccines

Request More Info